Brokerages Anticipate Global Blood Therapeutics, Inc. (NASDAQ:GBT) to Announce -$1.29 EPS

Wall Street analysts forecast that Global Blood Therapeutics, Inc. (NASDAQ:GBTGet Rating) will post earnings per share of ($1.29) for the current quarter, Zacks reports. Twelve analysts have made estimates for Global Blood Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.84) and the lowest estimate coming in at ($1.48). Global Blood Therapeutics posted earnings of ($1.21) per share during the same quarter last year, which suggests a negative year over year growth rate of 6.6%. The firm is scheduled to report its next earnings report after the market closes on Monday, January 1st.

According to Zacks, analysts expect that Global Blood Therapeutics will report full year earnings of ($4.76) per share for the current year, with EPS estimates ranging from ($7.57) to ($2.69). For the next fiscal year, analysts forecast that the firm will post earnings of ($3.12) per share, with EPS estimates ranging from ($5.74) to ($0.15). Zacks Investment Research’s EPS averages are an average based on a survey of research firms that that provide coverage for Global Blood Therapeutics.

Global Blood Therapeutics (NASDAQ:GBTGet Rating) last posted its quarterly earnings data on Wednesday, February 23rd. The company reported ($1.36) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.14) by ($0.22). The company had revenue of $56.10 million for the quarter, compared to analysts’ expectations of $55.45 million. Global Blood Therapeutics had a negative net margin of 155.63% and a negative return on equity of 102.42%. The business’s revenue for the quarter was up 35.8% on a year-over-year basis. During the same period in the previous year, the business earned ($1.00) earnings per share.

A number of equities research analysts have weighed in on the stock. Oppenheimer dropped their price target on shares of Global Blood Therapeutics from $92.00 to $86.00 and set an “outperform” rating for the company in a research report on Thursday, February 24th. StockNews.com started coverage on shares of Global Blood Therapeutics in a research note on Thursday, March 31st. They issued a “sell” rating for the company. Cantor Fitzgerald started coverage on shares of Global Blood Therapeutics in a research note on Thursday. They issued a “buy” rating and a $75.00 price target for the company. Cowen decreased their price target on shares of Global Blood Therapeutics from $72.00 to $67.00 in a research note on Thursday, February 24th. Finally, Morgan Stanley lifted their price target on shares of Global Blood Therapeutics from $28.00 to $31.00 and gave the stock an “equal weight” rating in a research note on Monday, February 28th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and ten have issued a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $60.29.

A number of large investors have recently added to or reduced their stakes in GBT. Nisa Investment Advisors LLC increased its position in Global Blood Therapeutics by 75.6% during the 1st quarter. Nisa Investment Advisors LLC now owns 1,510 shares of the company’s stock worth $52,000 after purchasing an additional 650 shares in the last quarter. DekaBank Deutsche Girozentrale boosted its holdings in Global Blood Therapeutics by 10.0% in the 1st quarter. DekaBank Deutsche Girozentrale now owns 24,250 shares of the company’s stock worth $848,000 after acquiring an additional 2,200 shares during the period. Mizuho Markets Americas LLC purchased a new position in shares of Global Blood Therapeutics during the 1st quarter valued at approximately $9,232,000. Vestmark Advisory Solutions Inc. boosted its stake in shares of Global Blood Therapeutics by 44.3% during the 1st quarter. Vestmark Advisory Solutions Inc. now owns 12,669 shares of the company’s stock valued at $439,000 after buying an additional 3,892 shares during the last quarter. Finally, Hennion & Walsh Asset Management Inc. lifted its stake in Global Blood Therapeutics by 8.6% during the first quarter. Hennion & Walsh Asset Management Inc. now owns 131,351 shares of the company’s stock worth $4,550,000 after purchasing an additional 10,385 shares during the last quarter.

Shares of NASDAQ GBT opened at $30.70 on Monday. The firm has a 50-day simple moving average of $32.59 and a 200-day simple moving average of $31.25. The stock has a market capitalization of $1.99 billion, a price-to-earnings ratio of -6.37 and a beta of 1.08. The company has a quick ratio of 8.45, a current ratio of 9.11 and a debt-to-equity ratio of 2.96. Global Blood Therapeutics has a 52 week low of $24.61 and a 52 week high of $42.47.

Global Blood Therapeutics Company Profile (Get Rating)

Global Blood Therapeutics, Inc, a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase II a clinical trial of adolescent and pediatric patients with SCD.

See Also

Get a free copy of the Zacks research report on Global Blood Therapeutics (GBT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Global Blood Therapeutics (NASDAQ:GBT)

Receive News & Ratings for Global Blood Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Blood Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.